Last reviewed · How we verify
LY2874455
At a glance
| Generic name | LY2874455 |
|---|---|
| Sponsor | Jacqueline Garcia, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Phase 1 Study of LY2874455 in Participants With Advanced Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2874455 CI brief — competitive landscape report
- LY2874455 updates RSS · CI watch RSS
- Jacqueline Garcia, MD portfolio CI